IL298623A - Liquid cannabis compositions and uses thereof - Google Patents
Liquid cannabis compositions and uses thereofInfo
- Publication number
- IL298623A IL298623A IL298623A IL29862322A IL298623A IL 298623 A IL298623 A IL 298623A IL 298623 A IL298623 A IL 298623A IL 29862322 A IL29862322 A IL 29862322A IL 298623 A IL298623 A IL 298623A
- Authority
- IL
- Israel
- Prior art keywords
- combinations
- group
- volatile
- cannabinoid
- pain
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 73
- 239000007788 liquid Substances 0.000 title claims description 31
- 240000004308 marijuana Species 0.000 title claims 2
- 150000003505 terpenes Chemical class 0.000 claims description 161
- 235000007586 terpenes Nutrition 0.000 claims description 161
- 229930003827 cannabinoid Natural products 0.000 claims description 79
- 239000003557 cannabinoid Substances 0.000 claims description 79
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims description 58
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 claims description 54
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 claims description 49
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 claims description 49
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 48
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 45
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 claims description 34
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 claims description 34
- MOYAFQVGZZPNRA-UHFFFAOYSA-N Terpinolene Chemical compound CC(C)=C1CCC(C)=CC1 MOYAFQVGZZPNRA-UHFFFAOYSA-N 0.000 claims description 34
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims description 31
- 241001471082 Colocasia bobone disease-associated cytorhabdovirus Species 0.000 claims description 31
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 claims description 31
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 claims description 30
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims description 29
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims description 29
- 229930007744 linalool Natural products 0.000 claims description 29
- XJPBRODHZKDRCB-UHFFFAOYSA-N trans-alpha-ocimene Natural products CC(=C)CCC=C(C)C=C XJPBRODHZKDRCB-UHFFFAOYSA-N 0.000 claims description 29
- 208000002193 Pain Diseases 0.000 claims description 28
- 150000007823 ocimene derivatives Chemical class 0.000 claims description 28
- 229940036350 bisabolol Drugs 0.000 claims description 27
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 claims description 24
- 235000001510 limonene Nutrition 0.000 claims description 24
- 229940087305 limonene Drugs 0.000 claims description 24
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 claims description 23
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 claims description 23
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 claims description 23
- 229940117948 caryophyllene Drugs 0.000 claims description 23
- FQTLCLSUCSAZDY-UHFFFAOYSA-N (+) E(S) nerolidol Natural products CC(C)=CCCC(C)=CCCC(C)(O)C=C FQTLCLSUCSAZDY-UHFFFAOYSA-N 0.000 claims description 21
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims description 21
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 21
- FQTLCLSUCSAZDY-ATGUSINASA-N Nerolidol Chemical compound CC(C)=CCC\C(C)=C\CC[C@](C)(O)C=C FQTLCLSUCSAZDY-ATGUSINASA-N 0.000 claims description 21
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 21
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims description 21
- WASNIKZYIWZQIP-AWEZNQCLSA-N nerolidol Natural products CC(=CCCC(=CCC[C@@H](O)C=C)C)C WASNIKZYIWZQIP-AWEZNQCLSA-N 0.000 claims description 21
- 238000009835 boiling Methods 0.000 claims description 20
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 claims description 20
- 229940116411 terpineol Drugs 0.000 claims description 20
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 claims description 19
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims description 18
- 229960005233 cineole Drugs 0.000 claims description 18
- 208000006820 Arthralgia Diseases 0.000 claims description 17
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 claims description 17
- 208000000112 Myalgia Diseases 0.000 claims description 16
- NDVASEGYNIMXJL-UHFFFAOYSA-N sabinene Chemical compound C=C1CCC2(C(C)C)C1C2 NDVASEGYNIMXJL-UHFFFAOYSA-N 0.000 claims description 16
- 208000007101 Muscle Cramp Diseases 0.000 claims description 13
- BXWQUXUDAGDUOS-UHFFFAOYSA-N gamma-humulene Natural products CC1=CCCC(C)(C)C=CC(=C)CCC1 BXWQUXUDAGDUOS-UHFFFAOYSA-N 0.000 claims description 13
- QBNFBHXQESNSNP-UHFFFAOYSA-N humulene Natural products CC1=CC=CC(C)(C)CC=C(/C)CCC1 QBNFBHXQESNSNP-UHFFFAOYSA-N 0.000 claims description 13
- QEBNYNLSCGVZOH-NFAWXSAZSA-N (+)-valencene Chemical compound C1C[C@@H](C(C)=C)C[C@@]2(C)[C@H](C)CCC=C21 QEBNYNLSCGVZOH-NFAWXSAZSA-N 0.000 claims description 12
- 239000001890 (2R)-8,8,8a-trimethyl-2-prop-1-en-2-yl-1,2,3,4,6,7-hexahydronaphthalene Substances 0.000 claims description 12
- TWVJWDMOZJXUID-SDDRHHMPSA-N Guaiol Chemical compound C1([C@H](CC[C@H](C2)C(C)(C)O)C)=C2[C@@H](C)CC1 TWVJWDMOZJXUID-SDDRHHMPSA-N 0.000 claims description 12
- 208000019695 Migraine disease Diseases 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- TWVJWDMOZJXUID-QJPTWQEYSA-N guaiol Natural products OC(C)(C)[C@H]1CC=2[C@H](C)CCC=2[C@@H](C)CC1 TWVJWDMOZJXUID-QJPTWQEYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 206010027599 migraine Diseases 0.000 claims description 12
- 208000004296 neuralgia Diseases 0.000 claims description 12
- 208000021722 neuropathic pain Diseases 0.000 claims description 12
- WCTNXGFHEZQHDR-UHFFFAOYSA-N valencene Natural products C1CC(C)(C)C2(C)CC(C(=C)C)CCC2=C1 WCTNXGFHEZQHDR-UHFFFAOYSA-N 0.000 claims description 12
- 208000004998 Abdominal Pain Diseases 0.000 claims description 11
- 208000013465 muscle pain Diseases 0.000 claims description 11
- -1 Carnene Chemical compound 0.000 claims description 10
- 229940065144 cannabinoids Drugs 0.000 claims description 10
- 230000036651 mood Effects 0.000 claims description 9
- NDVASEGYNIMXJL-NXEZZACHSA-N (+)-sabinene Natural products C=C1CC[C@@]2(C(C)C)[C@@H]1C2 NDVASEGYNIMXJL-NXEZZACHSA-N 0.000 claims description 8
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 claims description 8
- KQAZVFVOEIRWHN-UHFFFAOYSA-N alpha-thujene Natural products CC1=CCC2(C(C)C)C1C2 KQAZVFVOEIRWHN-UHFFFAOYSA-N 0.000 claims description 8
- 229930006696 sabinene Natural products 0.000 claims description 8
- 208000019901 Anxiety disease Diseases 0.000 claims description 7
- 201000009273 Endometriosis Diseases 0.000 claims description 7
- 206010019233 Headaches Diseases 0.000 claims description 7
- 208000000450 Pelvic Pain Diseases 0.000 claims description 7
- 230000036506 anxiety Effects 0.000 claims description 7
- 231100000869 headache Toxicity 0.000 claims description 7
- 229930006978 terpinene Natural products 0.000 claims description 7
- 150000003507 terpinene derivatives Chemical class 0.000 claims description 7
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 6
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 6
- 206010017999 Gastrointestinal pain Diseases 0.000 claims description 6
- 208000005392 Spasm Diseases 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 claims description 6
- 206010023230 Joint stiffness Diseases 0.000 claims description 5
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 5
- 206010049816 Muscle tightness Diseases 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 5
- 238000006114 decarboxylation reaction Methods 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 208000018198 spasticity Diseases 0.000 claims description 5
- 206010022998 Irritability Diseases 0.000 claims description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 4
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 claims description 4
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 claims description 4
- 239000007903 gelatin capsule Substances 0.000 claims description 4
- 206010022437 insomnia Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 claims description 3
- 206010013082 Discomfort Diseases 0.000 claims description 3
- 206010029216 Nervousness Diseases 0.000 claims description 3
- 206010038743 Restlessness Diseases 0.000 claims description 3
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 claims description 3
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 claims description 2
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 claims description 2
- 229930006722 beta-pinene Natural products 0.000 claims description 2
- 229930006739 camphene Natural products 0.000 claims description 2
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 claims description 2
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 11
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 56
- IGHTZQUIFGUJTG-UHFFFAOYSA-N cannabicyclol Chemical compound O1C2=CC(CCCCC)=CC(O)=C2C2C(C)(C)C3C2C1(C)CC3 IGHTZQUIFGUJTG-UHFFFAOYSA-N 0.000 description 44
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 34
- 229950011318 cannabidiol Drugs 0.000 description 34
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 34
- 241000218236 Cannabis Species 0.000 description 33
- 239000003921 oil Substances 0.000 description 31
- 235000019198 oils Nutrition 0.000 description 31
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 22
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 description 22
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 22
- ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 description 22
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 22
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 description 22
- 229960003453 cannabinol Drugs 0.000 description 22
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 13
- 239000000284 extract Substances 0.000 description 13
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 7
- 239000005792 Geraniol Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940113087 geraniol Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000000094 Chronic Pain Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000036626 alertness Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 229930006737 car-3-ene Natural products 0.000 description 5
- 229930007796 carene Natural products 0.000 description 5
- BQOFWKZOCNGFEC-UHFFFAOYSA-N carene Chemical compound C1C(C)=CCC2C(C)(C)C12 BQOFWKZOCNGFEC-UHFFFAOYSA-N 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 230000003961 neuronal insult Effects 0.000 description 5
- 230000003860 sleep quality Effects 0.000 description 5
- 230000004622 sleep time Effects 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- KXKOBIRSQLNUPS-UHFFFAOYSA-N 1-hydroxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene-2-carboxylic acid Chemical compound O1C(C)(C)C2=CC=C(C)C=C2C2=C1C=C(CCCCC)C(C(O)=O)=C2O KXKOBIRSQLNUPS-UHFFFAOYSA-N 0.000 description 2
- IBVJWOMJGCHRRW-UHFFFAOYSA-N 3,7,7-Trimethylbicyclo[4.1.0]hept-2-ene Chemical compound C1CC(C)=CC2C(C)(C)C12 IBVJWOMJGCHRRW-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- HRHJHXJQMNWQTF-UHFFFAOYSA-N cannabichromenic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCCCC)C(C(O)=O)=C2O HRHJHXJQMNWQTF-UHFFFAOYSA-N 0.000 description 2
- 239000002621 endocannabinoid Substances 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000010460 hemp oil Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- IBVJWOMJGCHRRW-DTWKUNHWSA-N 2-Carene Natural products C1CC(C)=C[C@H]2C(C)(C)[C@@H]12 IBVJWOMJGCHRRW-DTWKUNHWSA-N 0.000 description 1
- YJYIDZLGVYOPGU-XNTDXEJSSA-N 2-[(2e)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-XNTDXEJSSA-N 0.000 description 1
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 1
- SEEZIOZEUUMJME-VBKFSLOCSA-N Cannabigerolic acid Natural products CCCCCC1=CC(O)=C(C\C=C(\C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-VBKFSLOCSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 240000004543 Vicia ervilia Species 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 1
- YJYIDZLGVYOPGU-UHFFFAOYSA-N cannabigeroldivarin Natural products CCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-UHFFFAOYSA-N 0.000 description 1
- SEEZIOZEUUMJME-FOWTUZBSSA-N cannabigerolic acid Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-FOWTUZBSSA-N 0.000 description 1
- SEEZIOZEUUMJME-UHFFFAOYSA-N cannabinerolic acid Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-UHFFFAOYSA-N 0.000 description 1
- 229930191614 cannabinolic acid Natural products 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Alternative & Traditional Medicine (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
LIQUID CANNABIS COMPOSITIONS AND USES THEREOF Cross-Reference to Related Applications id="p-1" id="p-1" id="p-1" id="p-1" id="p-1"
id="p-1"
[001] The present application gains priority from U.S Provisional Patent Application Serial No. 63/032,681 filed 31 May, 2020 which is incorporated by reference as if fully set- forth herein.
Field of the Invention id="p-2" id="p-2" id="p-2" id="p-2" id="p-2"
id="p-2"
[002] The field of art to which this invention generally pertains is cannabinoid compositions, and more specifically to liquid cannabis compositions comprising at least two volatile terpenes and an oil-soluble carrier.
Background of the invention id="p-3" id="p-3" id="p-3" id="p-3" id="p-3"
id="p-3"
[003] Cannabis inflorescence is typically classified according to the cannabis species from which the inflorescence is obtained i.e. Sativa or Indica. For example, the Israeli Ministry of Health guidelines for permitted cannabis products refer to Sativa inflorescence and Indica inflorescence. Sativa inflorescence products are considered to be suitable for daytime administration, while Indica inflorescence products are considered to be suitable for nighttime administration. The difference is not due to the respective cannabinoid contents. id="p-4" id="p-4" id="p-4" id="p-4" id="p-4"
id="p-4"
[004] In contrast to cannabis inflorescence, commercially available cannabis oils are not generally classified according to the species from which they are derived, such that very few cannabis oils are specified as being Sativa cannabis oils or Indica cannabis oils. When such a distinction is made, the classification is based on the inflorescence from which the oil was prepared. One reason for the lack of distinction between Sativa and Indica oils in commercial products is that most of such oils contain a blend of extracts from inflorescence of the two species. However, a more important reason is that cannabis inflorescences contain significant amounts of nearly 20 different terpenes, having the formulae C H , C H O, C H and 16 10 18 15 24 C H O, wherein C terpenes are referred to as mono-terpenes and C terpenes are 26 10 15 sesquiterpenes. These terpenes differ considerably in their boiling points, which range between about 155ºC and about 320ºC. Furthermore, terpenes having the same chemical formula may 1 at least partially evaporate at ambient temperature.
Summary of the invention id="p-5" id="p-5" id="p-5" id="p-5" id="p-5"
id="p-5"
[005] According to an aspect of some embodiments of the present invention, there is provided a liquid composition comprising: (i) at least one cannabinoid, wherein at least 50% by weight of said cannabinoid is in decarboxylated form; (ii) at least two volatile terpenes, each having a boiling point of less than 230ºC at atmospheric pressure; (iii) an oil-soluble carrier; and (iv) optionally, at least one non-volatile terpene having a boiling point of at least 230ºC at atmospheric pressure. wherein (a) a total volatile terpene to total cannabinoid weight/weight ratio is greater than 0.01:1.0; (b) wherein when said non-volatile terpene is present, the total volatile terpenes to total non-volatile terpenes weight/weight ratio is greater than 0.3:1.0.
According to an aspect of some embodiments of the present invention, there is provided a method of treating a subject during a selected period of a day, comprising administering to the subject during said selected period a liquid composition comprising: (i) at least one cannabinoid, wherein at least 50% by weight of said cannabinoid is in decarboxylated form; (ii) at least two volatile terpenes, each having a boiling point of less than 230C at atmospheric pressure; (iii) an oil-soluble carrier; and (iv) optionally, at least one non-volatile terpene having a boiling point of at least 230C at atmospheric pressure. wherein (a) a total volatile terpene to total cannabinoid weight/weight ratio is greater than 0.01:1.0; (b) wherein when said non-volatile terpene is present, the total volatile terpenes to total non-volatile terpenes weight/weight ratio is greater than 0.3:1.0. 2 Detailed description of the invention id="p-6" id="p-6" id="p-6" id="p-6" id="p-6"
id="p-6"
[006] The present invention, in at least some embodiments thereof, relates to liquid cannabis compositions comprising at least two volatile terpenes and an oil-soluble carrier. id="p-7" id="p-7" id="p-7" id="p-7" id="p-7"
id="p-7"
[007] During decarboxylation of extracted cannabinoids for oil preparation, relatively high temperatures, typically in the range of 100-140ºC are required, which are quite close to the boiling point of the volatile terpenes (which are less than or equal to 230ºC) but are far from the boiling points of the less volatile terpenes (which are greater than 230ºC). As a result, during decarboxylation, volatile temperatures are removed while the less volatile terpenes are at least partially retained. This therefore changes not only the total content of the terpenes and the ratio between total terpenes and cannabinoids (both of which decrease), but also results in a decrease of the relative proportion of the volatile terpenes in the total terpene mixture. id="p-8" id="p-8" id="p-8" id="p-8" id="p-8"
id="p-8"
[008] The present Inventors have surprisingly found that important therapeutic properties are lost with that change in the proportion of the volatile terpenes, including distinction between composition that are better suited for administration at night and others that are better suited for administration during daytime. id="p-9" id="p-9" id="p-9" id="p-9" id="p-9"
id="p-9"
[009] The particulars shown herein are by way of example and for purposes of illustrative discussion of the various embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description making apparent to those skilled in the art how the several forms of the invention may be embodied in practice. id="p-10" id="p-10" id="p-10" id="p-10" id="p-10"
id="p-10"
[0010] The present invention will now be described by reference to more detailed embodiments. This invention may, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. id="p-11" id="p-11" id="p-11" id="p-11" id="p-11"
id="p-11"
[0011] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this 3 describing particular embodiments only and is not intended to be limiting of the invention. id="p-12" id="p-12" id="p-12" id="p-12" id="p-12"
id="p-12"
[0012] As used herein, the term "cannabinoid" refers to a compound that affects the endocannabinoid system. Cannabinoids are agonists or antagonists to receptors in the endocannabinoid system. id="p-13" id="p-13" id="p-13" id="p-13" id="p-13"
id="p-13"
[0013] As used herein, the term "THC" refers to THCa (tetrahydrocannabiniolic acid) and/or to THC (tetrahydrocannabiniol) unless indicated otherwise. As used herein, the term "CBD" refers to CBDa (cannabidiolic acid) and/or to CBD (cannabidiol) unless indicated otherwise. As used herein, the term "CBG" refers to CBGa (cannabigerolic acid) and/or to CBG (cannabigerol) unless indicated otherwise. As used herein, the term "CBN" refers to CBNa (Cannabinolic acid) and/or to CBN (cannabinol) unless indicated otherwise. As used herein, the term "CBC" refers to CBCa (cannabichromenic acid) and/or to CBC (Cannabichromene) unless indicated otherwise. As used herein, the term "CBL" refers to CBLa (Cannabicycol acid) and/or to CBL (Cannabicyclol) unless indicated otherwise. As used herein, the term "THCV" refers to THCVa (tetrahydrocannabivarin acid) and/or to THCV (tetrahydrocannabivarin) unless indicated otherwise. As used herein, the term "CBDV" refers to CBDVa (cannabigerovarin acid). id="p-14" id="p-14" id="p-14" id="p-14" id="p-14"
id="p-14"
[0014] As used herein, the term "cannabis oil" is intended to refer to an extract of a cannabis inflorescence, typically diluted in a vegetable oil such as olive oil, hemp oil, soybeanoil and sesame oil. id="p-15" id="p-15" id="p-15" id="p-15" id="p-15"
id="p-15"
[0015] As used herein, "terpene" is intended to include both terpenes and terpenoids. id="p-16" id="p-16" id="p-16" id="p-16" id="p-16"
id="p-16"
[0016] As used herein, the term "for administration at night" with regard to a composition refers to a composition suitable for administration prior to sleep, preferably prior to a sleep period of at least 5 hours, such as during the hours of darkness. According to some embodiments, a compound suitable for administration at night will have an extended effect of at least 5 hours, such as 5 hours, 6 hours, 7 hours, 8 hours or even more than 8 hours.
According to some embodiments, the composition enhances duration and/or quality of sleep. id="p-17" id="p-17" id="p-17" id="p-17" id="p-17"
id="p-17"
[0017] As used herein the term "for administration during daytime" with regard to a composition refers to a composition suitable for use during the hours in which the subject intends to be awake, such as a time between the subject waking from a night sleep and going to sleep the following night. According to some embodiments, the composition for 4 preferably increases energy and focus in the subject. id="p-18" id="p-18" id="p-18" id="p-18" id="p-18"
id="p-18"
[0018] As used herein the term "a specific period of a day" refers to a specific section during a 24 hour period, i.e. at night or during daytime. id="p-19" id="p-19" id="p-19" id="p-19" id="p-19"
id="p-19"
[0019] As used herein, the term "treating" includes ameliorating, mitigating, and reducing the instances of a disease or condition, or the symptoms of a disease or condition. id="p-20" id="p-20" id="p-20" id="p-20" id="p-20"
id="p-20"
[0020] As used herein, the term "administering" includes any mode of administration, such as oral, subcutaneous, sublingual, transmucosal, parenteral, intravenous, intra-arterial, buccal, sublingual, topical, vaginal, rectal, ophthalmic, otic, nasal, inhaled, intramuscular, intraosseous, intrathecal, and transdermal, or combinations thereof. "Administering" can also include providing a different compound that when ingested or delivered as above will necessarily transform into the compound that is desired to be administered, this type of "different compound" is often being referred to as a "Prodrug". "Administering" can also include prescribing or filling a prescription for a dosage form comprising a particular compound. "Administering" can also include providing directions to carry out a method involving a particular compound or a dosage form comprising the compound or compounds. id="p-21" id="p-21" id="p-21" id="p-21" id="p-21"
id="p-21"
[0021] Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches. id="p-22" id="p-22" id="p-22" id="p-22" id="p-22"
id="p-22"
[0022] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements. Every numerical range given throughout this specification will include every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein. "about" is intended to indicate +/-10% of that value. id="p-24" id="p-24" id="p-24" id="p-24" id="p-24"
id="p-24"
[0024] As used herein, the terms "comprising", "including", "having" and grammatical variants thereof are to be taken as specifying the stated features, integers, steps or components but do not preclude the addition of one or more additional features, integers, steps, components or groups thereof. These terms encompass the terms "consisting of" and "consisting essentially of". id="p-25" id="p-25" id="p-25" id="p-25" id="p-25"
id="p-25"
[0025] Additional advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. id="p-26" id="p-26" id="p-26" id="p-26" id="p-26"
id="p-26"
[0026] According to an aspect of some embodiments of the present invention, there is provided a liquid composition comprising: (i) at least one cannabinoid, wherein at least 50% by weight of said at least one cannabinoid is in decarboxylated form; (ii) at least two volatile terpenes, each having a boiling point of less than 230ººC at atmospheric pressure; (iii) an oil-soluble carrier; and (iv) optionally, at least one non-volatile terpene having a boiling point of at least 230ºC at atmospheric pressure. wherein (a) a total volatile terpene to total cannabinoid weight/weight ratio is greater than 0.01:1.0; (b) wherein when said non-volatile terpene is present, the total volatile terpenes to total non-volatile terpenes weight/weight ratio is greater than 0.3:1.0. id="p-27" id="p-27" id="p-27" id="p-27" id="p-27"
id="p-27"
[0027] According to an embodiment, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or even about 100% of the at least one cannabinoid is in decarboxylated form. id="p-28" id="p-28" id="p-28" id="p-28" id="p-28"
id="p-28"
[0028] According to an embodiment, each of said at least two volatile terpenes has a boiling point of less than 230ºCat atmospheric pressure, such as less than 220ºC, less than 210ºC, less than 200 ºC, less than 190 ºC, less than 180ºC, less than 170 ºC, or less than 160 ºC. According 6 from at least 150 ºC to less than 230 ºC at atmospheric pressure. id="p-29" id="p-29" id="p-29" id="p-29" id="p-29"
id="p-29"
[0029] According to an embodiment, said at least one non-volatile terpene has a boiling point of at least 230ºC at atmospheric pressure, such as at least 230 ºC, at least 240 ºC, at least 250 ºC, at least 260 ºC, at least 270 ºC, at least 280 ºC, at least 290 ºC, at least 300 ºC, at least 310 ºC, at least 320 ºC, at least 330 ºC, at least 340 ºC. According to an embodiment, said at least one non-volatile terpene has a boiling point in the range of from at least 230ºC to 350ºC at atmospheric pressure. id="p-30" id="p-30" id="p-30" id="p-30" id="p-30"
id="p-30"
[0030] According to an embodiment a total volatile terpene to total cannabinoid weight/weight ratio is greater than 0.01:1.0. According to various embodiments, said ratio is greater than 0.02:1, greater than 0.03:1 greater than 0.04:1, greater than 0.05:1 greater than 0.06:1, greater than 0.07:1 greater than 0.08:1, greater than 0.09:1, greater than 0.1:1, greater than 0.12:1 greater than 0.14:1, greater than 0.16:1, greater than 0.18:1, greater than 0.20:1 greater than 0.23:1 or greater than 0.25:1. According to an embodiment a total volatile terpene to total cannabinoid weight/weight ratio is less than 1:1, less than 0.8:1, less than 0.6:1 or less than 0.4:1. id="p-31" id="p-31" id="p-31" id="p-31" id="p-31"
id="p-31"
[0031] According to an embodiment a total non-volatile terpene to total cannabinoid weight/weight ratio is less than 0.6:1, less than 0.7:1, less than 0.5:1 or less than 0.4:1. id="p-32" id="p-32" id="p-32" id="p-32" id="p-32"
id="p-32"
[0032] According to an embodiment, the oil-soluble carrier is selected from the group consisting of olive oil, hemp oil, soybean oil and sesame oil, medium chain triglyceride (MCT). id="p-33" id="p-33" id="p-33" id="p-33" id="p-33"
id="p-33"
[0033] According to an embodiment, the liquid composition does not contain glycerol or glycols or contains glycerol and/or a glycol at less than 5% by weight. id="p-34" id="p-34" id="p-34" id="p-34" id="p-34"
id="p-34"
[0034] According to an embodiment, the liquid composition comprises at least two, such as two, three, four, five or more than five such volatile terpenes. id="p-35" id="p-35" id="p-35" id="p-35" id="p-35"
id="p-35"
[0035] According to an embodiment, a concentration of said cannabinoid in the composition is in the range of from 2 to 40%wt of the total composition, such as from 2, from , from 10, from 15, from 20, from 25, from 30, about from 35 or up to 40wt% of the total composition. id="p-36" id="p-36" id="p-36" id="p-36" id="p-36"
id="p-36"
[0036] According to an embodiment, said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof. 7 the group consisting of alpha-Pinene, beta-Pinene, Terpinene, Camphene, Myrcene, Ocimene, Valencene, Terpinolene, Limonene, Sabinene, Linalool, Carnene, Eucalyptol, Terpineol and combinations thereof. id="p-38" id="p-38" id="p-38" id="p-38" id="p-38"
id="p-38"
[0038] According to an embodiment, said at least one non-volatile terpene is selected from the group consisting of Caryophyllene, Humulene, Nerolidol, Guaiol, Bisabolol, Gernaiol and combinations thereof. id="p-39" id="p-39" id="p-39" id="p-39" id="p-39"
id="p-39"
[0039] According to an embodiment, the liquid composition is for administration at night, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof and wherein said at least two volatile terpenes are selected from the group consisting of Pinene, Terpinene, Champene, Myrcene, Ocimene, Valencene, Linalool, Terpineol and combinations thereof. According to one such embodiment, the liquid composition is for administration at night, and said at least two volatile terpenes are selected from the group consisting of Myrcene, Ocimene, Linalool, Terpineol and combinations thereof. id="p-40" id="p-40" id="p-40" id="p-40" id="p-40"
id="p-40"
[0040] According to an embodiment, the liquid composition is for administration during the day, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof and wherein said at least two volatile terpenes are selected from the group consisting of Pinene, Terpinolene, Limonene, Eucalyptol, Ocimene, Valencene and combinations thereof. According to one such embodiment, the liquid composition is for administration during the day and said at least two volatile terpenes are selected from the group consisting of Terpinolene, Eucalyptol, Pinene, Limonene and combinations thereof. id="p-41" id="p-41" id="p-41" id="p-41" id="p-41"
id="p-41"
[0041] According to an embodiment, said non-volatile terpene is present and the total volatile terpenes to total non-volatile terpene weight/weight ratio is greater than 0.3:1.
According to various embodiments, said ratio is greater than 0.4:1, greater than 0.5:1 greater than 0.6:1, greater than 0.7:1 greater than 0.8:1, greater than 0.9:1 greater than 1:1, between 1:1 and 1.5:1, between 1:5:1 and 2:1, between 2:1 and 2.5:1, between 2.5:1 and 3:1, between 3:1 and 3.5:1, between 3.5:1 and 4:1, between 4:1 and 4.5:1 or between 4.5:1 and 5:1.
According to an embodiment, the total volatile terpenes to total non-volatile terpene weight/weight ratio is less than 10:1, less than 9:1 or less than 8:1. 8 non-cannabinoid and non-terpene cannabis compounds, such as at least two, at least three, at least four, or at least five non-cannabinoid and non-terpene cannabis compounds. According to an embodiment, there is provided a dosage form comprising the liquid composition as disclosed herein. According to one such embodiment, the dosage form comprises a capsule, such as a gelatin capsule, including a hard gelatin capsule or a soft gelatin capsule. id="p-43" id="p-43" id="p-43" id="p-43" id="p-43"
id="p-43"
[0043] According to an aspect of some embodiments of the present invention, there is provided a method for the preparation of a liquid composition as disclosed herein, the method comprising a. providing at least one cannabinoid; b. subjecting said at least one cannabinoid to a decarboxylation process to obtain a cannabinoid wherein at least 50% by weight of said cannabinoid is in decarboxylated form; c. adding to said cannabinoid wherein at least 50% by weight of said cannabinoid is in decarboxylated form said at least two volatile terpenes, each having a boiling point of less than 230C at atmospheric pressure and an oil soluble carrier and optionally at least one non-volatile terpene having a boiling point of at least 230ºC at atmospheric pressure in amounts such that a total volatile terpene to total cannabinoid weight/weight ratio is greater than 0.01:1.0 and wherein when said non-volatile terpene is present, the total volatile terpenes to total non-volatile terpenes weight/weight ratio is greater than 0.3:1.0. id="p-44" id="p-44" id="p-44" id="p-44" id="p-44"
id="p-44"
[0044] According to an aspect of some embodiments of the present invention, there is provided a method of treating a subject during a selected period of a day, comprising administering to the subject during said selected period a liquid composition comprising: (i) at least one cannabinoid, wherein at least 50% by weight of said cannabinoid is in decarboxylated form; (ii) at least two volatile terpenes, each having a boiling point of less than 230ºC at atmospheric pressure; (iii) an oil-soluble carrier; and (iv) optionally, at least one non-volatile terpene having a boiling point of at least 230ºC at atmospheric pressure. wherein 9 0.01:1.0; (d) wherein when said non-volatile terpene is present, the total volatile terpenes to total non-volatile terpenes weight/weight ratio is greater than 0.3:1.0. id="p-45" id="p-45" id="p-45" id="p-45" id="p-45"
id="p-45"
[0045] According to an embodiment, said selected period is during daytime. According to one such embodiment, said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof and wherein said at least two volatile terpenes are selected from the group consisting of Pinene, Terpinolene, Limonene, Eucalyptol, Ocimene, Valencene and combinations thereof. id="p-46" id="p-46" id="p-46" id="p-46" id="p-46"
id="p-46"
[0046] According to an embodiment, said selected period is at night. According to one such embodiment, said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof and wherein said at least two volatile terpenes are selected from the group consisting of Pinene, Terpinene, Champene, Myrcene, Ocimene, Valencene, Linalool, Terpineol and combinations thereof. id="p-47" id="p-47" id="p-47" id="p-47" id="p-47"
id="p-47"
[0047] According to an embodiment wherein said selected period is at night, said treating comprises treating insomnia, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, myrcene, ocimene, linalool and combinations thereof, and wherein said non-volatile terpene is selected from the group consisting of caryophyllene, nerolidol, bisabolol and combinations thereof. id="p-48" id="p-48" id="p-48" id="p-48" id="p-48"
id="p-48"
[0048] According to an embodiment wherein said selected period is at night, said treating comprises treating a condition selected from the group consisting of pain, joint pain, joint stiffness, arthralgia, arthritis, osteoarthritis, muscle pain, myalgia, spasticity, muscle tension, cramps, spasms, gastrointestinal pain, abdominal pain, pelvic pain, endometriosis, dysmenorrhea and combinations thereof wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, myrcene, limonene, linalool, terpineol and combinations thereof, and wherein said non- volatile terpene is selected from the group consisting of caryophyllene, humulene, nerolidol, bisabolol and combinations thereof. id="p-49" id="p-49" id="p-49" id="p-49" id="p-49"
id="p-49"
[0049] According to an embodiment wherein said selected period is during daytime, said treating comprises treating a condition selected from the group consisting of pain, joint pain, tension, cramps, spasms, gastrointestinal pain, abdominal pain, pelvic pain, endometriosis, dysmenorrhea and combinations thereof, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, myrcene, limonene, linalool, terpineol and combinations thereof, and wherein said non- volatile terpene is selected from the group consisting of caryophyllene, humulene, nerolidol, bisabolol and combinations thereof. id="p-50" id="p-50" id="p-50" id="p-50" id="p-50"
id="p-50"
[0050] According to an embodiment wherein said selected period is at night, said treating comprises treating a condition selected from the group consisting of pain, neuropathic pain, migraine, headache and combinations thereof wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, myrcene, ocimene, linalool and combinations thereof, and wherein said non-volatile terpene is selected from the group consisting of caryophyllene, bisabolol and combinations thereof. id="p-51" id="p-51" id="p-51" id="p-51" id="p-51"
id="p-51"
[0051] According to an embodiment wherein said selected period is during daytime, said treating comprises treating a condition selected from the group consisting of pain, neuropathic pain, migraine, headache and combinations thereof, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, myrcene, ocimene and combinations thereof, and wherein said non- volatile terpene is selected from the group consisting of caryophyllene, bisabolol and combinations thereof. id="p-52" id="p-52" id="p-52" id="p-52" id="p-52"
id="p-52"
[0052] According to an embodiment wherein said selected period is during daytime, said treating comprises treating a condition selected from the group consisting of anxiety, stress, depression, irritability, general discomfort, nervousness, restless, mood problems and combinations thereof, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, limonene, terpinolene, eucalyptol, linalool and combinations thereof, and wherein said non- volatile terpene is selected from the group consisting of caryophyllene, humulene, nerolidol, guaiol, bisabolol and combinations thereof. 11 provided the composition as disclosed herein, for use in treating a subject during a selected period of a day. id="p-54" id="p-54" id="p-54" id="p-54" id="p-54"
id="p-54"
[0054] According to some embodiments, said selected period is during daytime. id="p-55" id="p-55" id="p-55" id="p-55" id="p-55"
id="p-55"
[0055] According to some embodiments, said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof and wherein said at least two volatile terpenes are selected from the group consisting of Pinene, Terpinolene, Limonene, Eucalyptol, Ocimene, Valencene and combinations thereof. id="p-56" id="p-56" id="p-56" id="p-56" id="p-56"
id="p-56"
[0056] According to some embodiments, said selected period is at night. id="p-57" id="p-57" id="p-57" id="p-57" id="p-57"
id="p-57"
[0057] According to some embodiments, said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof and wherein said at least two volatile terpenes are selected from the group consisting of Pinene, Terpinene, Champene, Myrcene, Ocimene, Valencene, Linalool, Terpineol and combinations thereof. id="p-58" id="p-58" id="p-58" id="p-58" id="p-58"
id="p-58"
[0058] According to some embodiments, said treating comprises treatment of insomnia, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, myrcene, ocimene, linalool and combinations thereof, and wherein said non-volatile terpene is selected from the group consisting of caryophyllene, nerolidol, bisabolol and combinations thereof. id="p-59" id="p-59" id="p-59" id="p-59" id="p-59"
id="p-59"
[0059] According to some embodiments, said treating comprises treating a condition selected from the group consisting of pain, joint pain, joint stiffness, arthralgia, arthritis, osteoarthritis, muscle pain, myalgia, spasticity, muscle tension, cramps, spasms, gastrointestinal pain, abdominal pain, pelvic pain, endometriosis, dysmenorrhea and combinations thereof wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, myrcene, limonene, linalool, terpineol and combinations thereof, and wherein said non-volatile terpene is selected from the group consisting of caryophyllene, humulene, nerolidol, bisabolol and combinations thereof. id="p-60" id="p-60" id="p-60" id="p-60" id="p-60"
id="p-60"
[0060] According to some embodiments, said treating comprises treating a condition selected from the group consisting of pain, joint pain, joint stiffness, arthralgia, arthritis, osteoarthritis, muscle pain, myalgia, spasticity, muscle tension, cramps, spasms, gastrointestinal pain, abdominal pain, pelvic pain, endometriosis, dysmenorrhea and 12 consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, myrcene, limonene, linalool, terpineol and combinations thereof, and wherein said non-volatile terpene is selected from the group consisting of caryophyllene, humulene, nerolidol, bisabolol and combinations thereof. id="p-61" id="p-61" id="p-61" id="p-61" id="p-61"
id="p-61"
[0061] According to some embodiments, said treating comprises treating a condition selected from the group consisting of pain, neuropathic pain, migraine, headache and combinations thereof wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, myrcene, ocimene, linalool and combinations thereof, and wherein said non-volatile terpene is selected from the group consisting of caryophyllene, bisabolol and combinations thereof. id="p-62" id="p-62" id="p-62" id="p-62" id="p-62"
id="p-62"
[0062] According to some embodiments, said treating comprises treating a condition selected from the group consisting of pain, neuropathic pain, migraine, headache and combinations thereof, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, myrcene, ocimene and combinations thereof, and wherein said non-volatile terpene is selected from the group consisting of caryophyllene, bisabolol and combinations thereof. id="p-63" id="p-63" id="p-63" id="p-63" id="p-63"
id="p-63"
[0063] According to some embodiments, said treating comprises treating a condition selected from the group consisting of anxiety, stress, depression, irritability, general discomfort, nervousness, restless, mood problems and combinations thereof, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, limonene, terpinolene, eucalyptol, linalool and combinations thereof, and wherein said non-volatile terpene is selected from the group consisting of caryophyllene, humulene, nerolidol, guaiol, bisabolol and combinations thereof. 13 id="p-64" id="p-64" id="p-64" id="p-64" id="p-64"
id="p-64"
[0064] EXAMPLES: Examples 1-9: Exemplary liquid compositions for administration during nighttime to treat insomnia are presented in Tables 1-3 below.
Table 1 Terpene Formula Example 1 Example 2 Example 3 Cannabinoids (%) THC 15 15 15 CBD 3 3 3 Volatile Terpenes (%) A-pinene C10H16 0.30 <0.01 0.23 B-pinene C10H16 <0.01 <0.01 <0.01 Sabinene C10H16 <0.01 <0.01 <0.01 B-Myrcene C10H16 0.38 0.41 0.30 Carene C10H16 <0.01 <0.01 <0.01 Ocimene C10H16 <0.01 0.41 0.20 Limonene C10H16 0.02 0.02 0.02 Terpinolene C10H16 <0.01 <0.01 <0.01 Eucalyptol C10H18O <0.01 <0.01 <0.01 Linalool C10H18O 0.04 0.41 0.23 Iaopulegol C10H18O <0.01 <0.01 <0.01 Terpineol C10H18O <0.01 <0.01 <0.01 Non-Volatile Terpenes (%) Geraniol C10H18O <0.01 <0.01 <0.01 B-caryophyllene C15H24 0.17 0.17 0.17 A-Humulene C15H24 0.06 0.06 0.06 Nerolidol C15H26O 0.40 0.02 0.23 Guaiol C15H26O 0.07 0.07 0.07 A-Bisabolol C15H26O 0.30 0.15 0.23 Table 2 Terpene Formula Example 4 Example 5 Example 6 Cannabinoids (%) THC 10 10 10 CBD 10 10 10 Volatile Terpenes (%) A-pinene C10H16 0.30 <0.01 0.23 B-pinene C10H16 <0.01 <0.01 <0.01 Sabinene C10H16 <0.01 <0.01 <0.01 B-Myrcene C10H16 0.38 0.41 0.30 Carene C10H16 <0.01 <0.01 <0.01 Ocimene C10H16 <0.01 0.41 0.20 Limonene C10H16 0.02 0.02 0.02 Terpinolene C10H16 <0.01 <0.01 <0.01 Eucalyptol C10H18O <0.01 <0.01 <0.01 14 Iaopulegol C10H18O <0.01 <0.01 <0.01 Terpineol C10H18O <0.01 <0.01 <0.01 Non-Volatile Terpenes (%) Geraniol C10H18O <0.01 <0.01 <0.01 B-caryophyllene C15H24 0.17 0.17 0.17 A-Humulene C15H24 0.06 0.06 0.06 Nerolidol C15H26O 0.40 0.02 0.23 Guaiol C15H26O 0.07 0.07 0.07 A-Bisabolol C15H26O 0.30 0.15 0.23 Table 3 Terpene Formula Example 7 Example 8 Example 9 Cannabinoids (%) THC 3 3 3 CBD 15 15 15 Volatile Terpenes (%) A-pinene C10H16 0.30 <0.01 0.23 B-pinene C10H16 <0.01 <0.01 <0.01 Sabinene C10H16 <0.01 <0.01 <0.01 B-Myrcene C10H16 0.38 0.41 0.30 Carene C10H16 <0.01 <0.01 <0.01 Ocimene C10H16 <0.01 0.41 0.20 Limonene C10H16 0.02 0.02 0.02 Terpinolene C10H16 <0.01 <0.01 <0.01 Eucalyptol C10H18O <0.01 <0.01 <0.01 Linalool C10H18O 0.04 0.41 0.23 Iaopulegol C10H18O <0.01 <0.01 <0.01 Terpineol C10H18O <0.01 <0.01 <0.01 Non-Volatile Terpenes (%) Geraniol C10H18O <0.01 <0.01 <0.01 B-caryophyllene C15H24 0.17 0.17 0.17 A-Humulene C15H24 0.06 0.06 0.06 Nerolidol C15H26O 0.40 0.02 0.23 Guaiol C15H26O 0.07 0.07 0.07 A-Bisabolol C15H26O 0.30 0.15 0.23 id="p-65" id="p-65" id="p-65" id="p-65" id="p-65"
id="p-65"
[0065] Examples 10-11: Exemplary liquid compositions for administration during nighttime to treat pain, e.g. pain associated with headaches, migraine, neuropathic pain or combinations thereof are presented in Table 4 below.
Table 4 Terpene Formula Example 10, for Example 11, for nighttime nighttime Cannabinoids (%) CBD 3 3 Volatile Terpenes (%) A-pinene C10H16 <0.01 0.23 B-pinene C10H16 <0.01 0.23 Sabinene C10H16 <0.01 <0.01 B-Myrcene C10H16 0.48 0.23 Carene C10H16 <0.01 <0.01 Ocimene C10H16 <0.01 0.20 Limonene C10H16 0.02 0.02 Terpinolene C10H16 <0.01 <0.01 Eucalyptol C10H18O <0.01 <0.01 Linalool C10H18O 0.48 0.23 Iaopulegol C10H18O <0.01 <0.01 Terpineol C10H18O <0.01 <0.01 Non-Volatile Terpenes (%) Geraniol C10H18O <0.01 <0.01 B- C15H24 caryophylle 0.48 0.23 ne A- C15H24 0.06 0.06 Humulene Nerolidol C15H26O 0.02 0.02 Guaiol C15H26O 0.07 0.07 A-Bisabolol C15H26O 0.10 0.23 id="p-66" id="p-66" id="p-66" id="p-66" id="p-66"
id="p-66"
[0066] Examples 12-16: Exemplary liquid compositions for administration during daytime or during nighttime to treat pain, e.g. pain associated with pelvic pain, endometriosis, muscle cramps, muscle pain, joint pain or combinations thereof are presented in Table 5 below.
Table 5 Terpene Formula Example Example Example Example Example 12, for 13, for 14, for 15, for 16, for nighttime daytime daytime nighttime nighttime Cannabinoids (%) THC 10 10 10 10 15 CBD 10 10 10 10 3 Volatile Terpenes (%) A-pinene C10H16 0.40 0.30 0.30 0.30 0.30 B-pinene C10H16 <0.01 <0.01 <0.01 <0.01 <0.01 Sabinene C10H16 <0.01 <0.01 <0.01 <0.01 <0.01 B-Myrcene C10H16 0.23 0.30 0.23 0.23 0.23 Carene C10H16 <0.01 <0.01 <0.01 <0.01 <0.01 Ocimene C10H16 <0.01 <0.01 <0.01 <0.01 <0.01 Limonene C10H16 0.01 0.23 0.15 0.2 0.15 Terpinolene C10H16 <0.01 <0.01 <0.01 <0.01 <0.01 Eucalyptol C10H18O <0.01 <0.01 <0.01 <0.01 <0.01 Linalool C10H18O 0.03 0.30 0.23 0.23 0.23 Iaopulegol C10H18O <0.01 <0.01 <0.01 <0.01 <0.01 16 Non-Volatile Terpenes (%) Geraniol C10H18O <0.01 <0.01 <0.01 <0.01 <0.01 B- C15H24 0.23 0.23 0.35 0.30 0.30 caryophyllene A-Humulene C15H24 0.04 0.04 0.04 0.18 0.15 Nerolidol C15H26O 0.17 0.01 0.01 0.01 0.02 Guaiol C15H26O 0.04 0.04 0.04 0.04 0.07 A-Bisabolol C15H26O 0.40 0.10 0.30 0.30 0.30 id="p-67" id="p-67" id="p-67" id="p-67" id="p-67"
id="p-67"
[0067] Examples 17-20: Exemplary liquid compositions for administration during daytime to treat anxiety, stress, depression, irritability, discomfort or combinations thereof are presented in Table 6 below.
Table 6 Terpene Formula Example 17, Example 18, Example 19, Example 20, for daytime for da time for daytime for daytime Cannabinoids (%) THC 3 3 3 3 CBD 15 15 15 15 Volatile Terpenes (%) A-pinene C10H16 <0.01 0.23 <0.01 0.23 B-pinene C10H16 <0.01 <0.01 <0.01 <0.01 Sabinene C10H16 <0.01 <0.01 <0.01 <0.01 B-Myrcene C10H16 <0.01 <0.01 <0.01 0.2 Carene C10H16 <0.01 <0.01 <0.01 <0.01 Ocimene C10H16 <0.01 <0.01 <0.01 <0.01 Limonene C10H16 0.38 0.23 0.38 0.23 Terpinolene C10H16 0.15 0.15 0.15 0.15 Eucalyptol C10H18O 0.15 <0.01 0.15 <0.01 Linalool C10H18O 0.38 0.23 0.38 0.23 Iaopulegol C10H18O <0.01 <0.01 <0.01 <0.01 Terpineol C10H18O <0.01 <0.01 <0.01 <0.01 Non-Volatile Terpenes (%) Geraniol C10H18O <0.01 <0.01 0.2 0.2 B- C15H24 0.3 0.23 0.38 0.23 caryophyllene A-Humulene C15H24 0.01 0.01 0.01 0.03 Nerolidol C15H26O 0.23 0.15 0.15 0.1 Guaiol C15H26O 0.01 0.1 0.01 0.23 A-Bisabolol C15H26O 0.02 0.30 0.03 0.30 id="p-68" id="p-68" id="p-68" id="p-68" id="p-68"
id="p-68"
[0068] Example 21: Treatment and/or management of specified conditions Materials and Methods 17 id="p-69" id="p-69" id="p-69" id="p-69" id="p-69"
id="p-69"
[0069] Compositions were prepared as follows: I. Non-terpene-enriched ("NE") cannabis oil extracts: a. Inflorescence of a THCa-rich strain of Cannabis was extracted with ethanol at 10 volume of ethanol per unit weight of inflorescence. The residual plant material was filtered and the filtrate was concentrated by ethanol distillation to provide an extract. The extract was o winterized for removing waxes (kept in a freezer at -18 C for 24 hours and then filtered). Then, the extract was heated to 120°C for about an hour to convert THCa to THC (decarboxylation) so as to produce a THC-rich extract. The weight percent of THC in the THC-rich extract was determined using a standardized validated High Performance Liquid Chromatography (HPLC) procedure. b. CBD isolate was purchased from Clever Leaves (Colombia). CBD concentration was confirmed using a standardized validated High Performance Liquid Chromatography (HPLC) procedure. c. The THC-rich extract and the CBD isolate were mixed at various ratios and combined with olive oil to produce non-enriched (NE) extracts as controls as detailed in Table 7 below.
II. Terpene-enriched ("NE") cannabis oil extracts: a. Terpene isolates were purchased from Vigon International, Inc. (Pennsylvania) and concentrations were confirmed using a standardized, validated Gas Chromatography (GC) procedure. b. Terpene-enriched cannabis oil extracts (Examples 1-3, 12-14 and 19-20) were prepared by adding certain terpenes to the NE compositions as prepared above to produce the terpene- enriched extracts identified in the above examples as detailed in Tables 1, 5 and 6 above. id="p-70" id="p-70" id="p-70" id="p-70" id="p-70"
id="p-70"
[0070] Test compositions according to Examples 1-3, 12-14 and 19-20 were administered to adult, human volunteers to test efficacy in the treatment and/or management of various conditions as specified below. id="p-71" id="p-71" id="p-71" id="p-71" id="p-71"
id="p-71"
[0071] Efficacy of the test compositions was compared to that of non-enriched control compositions NE1, NE2, NE3 having the same THC and CBD content as that of the test compositions, with no terpene enrichment, as detailed in Table 7 below. Specifically, the compositions of Examples 1-3 were compared to control composition NE1; the compositions of Examples 12-14 were compared to control composition NE2; and the compositions of Examples 19-20 were compared to control composition NE3. 18 enriched" may naturally comprise low amounts (less than 0.1%) of volatile terpenes upon preparation from cannabis plant material. Thus the term "non-enriched" is intended to refer to compositions to which no volatile terpenes are artificially added.
Table 7 NE1 NE2 NE3 THC (%) 15 10 3 CBD (%) 3 10 15 Alpha Pinene Myrcene 0.02 0.01 Limonene Linalool 0.05 0.03 0.01 Terpineol Eucalyptol Geraniol Ocimene 0.01 Caryophyllene 0.2 0.12 0.04 Nerolidol Bisabolol 0.15 0.10 0.03 Humulene 0.06 0.04 0.01 Guaiol (ppm) 0.07 0.04 0.01 id="p-73" id="p-73" id="p-73" id="p-73" id="p-73"
id="p-73"
[0073] Subjects and questionnaires a. All subjects were Israeli patients, each of whom had been issued a license to use medical cannabis for the treatment of chronic pain, neuronal disease, neuronal damage, cancer, or trauma, by the Israeli Ministry of Health. b. Subjects eligible for participation in these studies were required to currently be on a regimen of non-enriched (NE) cannabis oils (NE1, NE2 or NE3, sublingually administered) for the treatment of chronic pain, neuronal disease, neuronal damage, cancer, or trauma. NE cannabis oils were self-administered by each subject, at home. Each subject completed questionnaires to assess the efficacy of their current NE cannabis oil treatment. Each subject 19 treatment. Average dose of the NE cannabis oil treatment was about 4.2 drops. c. Subjects were then provided with a terpene-enriched oil according to one of examples 1-3, 12-14 and 19-20. The assignment of terpene-enriched oil to each subject was based on the THC/CBD ratio of the subject’s current NE cannabis oil treatment. Subjects were instructed to self-administer the terpene-enriched oils at home for 1 week, starting with the same or similar doses and frequencies as those they had followed for the NE cannabis oil treatment. After 1 week, subjects were instructed to continue self-administration of the terpene-enriched oils and to complete questionnaires to assess the efficacy of the terpene-enriched oil treatment. Each subject completed questionnaires for 5 days of the continued terpene-enriched treatment, each questionnaire referring to the previous day’s treatment. Average dose of terpene-enriched cannabis oil was 3.8 drops. d. Pain treatment efficacy questionnaire: Subjects having been issued a license to use medical cannabis for the treatment of pain related to chronic pain, neuronal disease, neuronal damage, or cancer, i.e., muscle pain, joint pain, migraine, neuropathic pain, abdominal pain, were asked to rate their pain relief efficacy on a scale of -10 to 10 using an extended Visual Analog Scale/Numeric Pain rating Scale (VAS/NPRS), which is customary in the field of pain management and treatment. With this scale, "10" indicated no pain, while "-10" indicates major worsening of pain. e. Depression/Anxiety efficacy questionnaire: Subjects having been issued a license to use medical cannabis for the treatment of depression and/or anxiety related to chronic pain, neuronal disease, neuronal damage, cancer, or trauma were asked to rate their mood and/or calmness using a -8 to 8 scale, which is customary in the field of mood and anxiety management and treatment. f. Sleep efficacy questionnaire: Subjects having been issued a license to use medical cannabis for the treatment of sleep-related issues related to chronic pain, neuronal disease, neuronal damage, cancer, or trauma were asked to rate their sleep quality, time to falling asleep, overall sleep time, sleep continuity, and/or next day alertness using a -8 to 8 scale, which is customary in the field of sleep management and treatment.
Results are presented in Tables 8-10 below.
As seen from Tables 8-10, improvements observed in each study were markedly better for the terpene-enriched test compositions, as compared to the non- enriched (NE) control compositions.
Table 11 presents data averaged across all subjects for all NE and terpene-enriched cannabis oils and t-test values comparing efficacy or the NE oils to that of the terpene-enriched oils. The t-test indicates that the terpene-enriched oils were statistically significantly superior to the NE oils.
Table 8 Average Efficacy Condition Treated NE1 Examples 1, 2, 3 n=10 Migraine 3.0 3.8 abdominal pain 3.2 4.6 Joint pain 4.0 5.8 Muscle pain 3.8 6.1 Neuropathic pain 3.9 5.6 Mood 4.0 5.1 Calmness 5.7 6.0 Sleep quality 5.4 6.6 Falling a sleep 4.2 5.7 Overall sleep time 4.1 5.8 Sleep continuity 3.3 5.5 Alertness 2.0 3.0 Table 9 Averaged Efficacy Condition Treated NE2 Examples 12, 13, 14 n=6 Migraine 0.7 3.4 abdominal pain 1.8 5.0 21 Condition Treated NE2 Examples 12, 13, 14 Joint pain 1.7 4.4 Muscle pain 2.1 4.2 Neuropathic pain 1.6 5.2 Mood 1.6 3.4 Calmness 2.3 3.4 Sleep quality 2.7 4.0 Falling a sleep 1.4 3.4 Overall sleep time 2.7 3.9 Sleep continuity 2.0 4.0 Alertness 0.9 2.0 Table 10 Averaged Efficacy Condition Treated NE3 Examples 19, 20 n=6 Migraine 2.3 5.2 abdominal pain 4.5 7.0 Joint pain 4.2 6.5 Muscle pain 5.0 7.2 Neuropathic pain 4.4 7.2 Mood 2.3 3.9 Calmness 3.3 4.5 Sleep quality 3.2 4.8 Falling a sleep 3.5 4.6 Overall sleep time 3.3 4.0 Sleep continuity 3.2 4.3 Alertness 1.9 1.3 22 Averaged Efficacy for Condition Averaged Efficacy Examples 1-3, 1 Treated for NE1, NE2, NE3 12-14, 19-20 t test n=24 Migraine 2.2 4.1 0.021 abdominal pain 3.2 5.5 0.005 Joint pain 3.4 5.5 0.001 Muscle pain 3.7 5.8 0.001 Neuropathic pain 3.4 5.9 0.003 Mood 2.6 4.3 0.001 Calmness 3.8 5.0 0.008 Sleep quality 4.1 5.4 0.005 Falling a sleep 3.2 4.8 0.005 Overall sleep time 3.5 4.8 0.015 Sleep continuity 2.9 4.8 0.001 Alertness 1.5 2.5 0.096 1 p<0.05 indicates significant differences between the results of the NE and E oils. 23
Claims (23)
1. A liquid composition comprising: (i) at least one cannabinoid, wherein at least 50% by weight of said cannabinoid is in decarboxylated form; (ii) at least two volatile terpenes, each having a boiling point of less than 230ºC at atmospheric pressure; (iii) an oil-soluble carrier; and (iv) optionally, at least one non-volatile terpene having a boiling point of at least 230ºC at atmospheric pressure. wherein (a) a total volatile terpene to total cannabinoid weight/weight ratio is greater than 0.01:1.0; and (b) wherein when said non-volatile terpene is present, the total volatile terpenes to total non-volatile terpenes weight/weight ratio is greater than 0.3:1.0.
2. The liquid composition of Claim 1, wherein a concentration of said cannabinoid in the composition is in the range of from 2 to 40%wt of the total composition.
3. The liquid composition of Claim 1, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof.
4. The liquid composition of Claim 1, wherein said at least two volatile terpenes are selected from the group consisting of alpha-Pinene, beta-Pinene, Terpinene, Camphene, Myrcene, Ocimene, Valencene, Terpinolene, Limonene, Sabinene, Linalool, Carnene, Eucalyptol, Terpineol and combinations thereof.
5. The liquid composition of Claim 1, wherein said at least one non-volatile terpene is selected from the group consisting of Caryophyllene, Humulene, Nerolidol, Guaiol, Bisabolol, Gernaiol and combinations thereof.
6. The liquid composition of Claim 1 for administration at night, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof and wherein said at least two volatile terpenes are selected from the group consisting of Pinene, Terpinene, Champene, Myrcene, Ocimene, Valencene, Linalool, Terpineol and combinations thereof. 24
7. The liquid composition of Claim 1 for administration during daytime, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof and wherein said at least two volatile terpenes are selected from the group consisting of Pinene, Terpinolene, Limonene, Eucalyptol, Ocimene, Valencene and combinations thereof.
8. The liquid composition of Claim 1, wherein said non-volatile terpene is present and wherein the non-volatile terpene to total cannabinoids weight/weight ratio is less than 0.6:1.0.
9. The liquid composition of Claim 1, further comprising at least two non-cannabinoid and non-terpene cannabis compounds.
10. A dosage form comprising the liquid composition of Claim 1.
11. The dosage form of Claim 10, comprising a gelatin capsule.
12. A method for the preparation of the liquid composition of Claim 1 comprising a. providing at least one cannabinoid; b. subjecting said at least one cannabinoid to a decarboxylation process to obtain a cannabinoid wherein at least 50% by weight of said cannabinoid is in decarboxylated form; c. adding to said cannabinoid wherein at least 50% by weight of said cannabinoid is in decarboxylated form said at least two volatile terpenes, each having a boiling point of less than 230C at atmospheric pressure and an oil soluble carrier and optionally at least one non- volatile terpene having a boiling point of at least 230C at atmospheric pressure in amounts such that a total volatile terpene to total cannabinoid weight/weight ratio is greater than 0.01:1.0 and wherein when said non-volatile terpene is present, the total volatile terpenes to total non- volatile terpenes weight/weight ratio is greater than 0.3:1.0.
13. The composition of any one of claims 1 to 9, for use in treating a subject during a selected period of a day.
14. The composition for use of claim 13, wherein said selected period is during daytime.
15. The composition for use of claim 13, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof and wherein said at least two volatile terpenes are selected from the group consisting of Pinene, Terpinolene, Limonene, Eucalyptol, Ocimene, Valencene and combinations thereof.
16. The composition for use of claim 13, wherein said selected period is at night. 25
17. The composition for use of claim 16, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof and wherein said at least two volatile terpenes are selected from the group consisting of Pinene, Terpinene, Champene, Myrcene, Ocimene, Valencene, Linalool, Terpineol and combinations thereof.
18. The composition for use of claim 16, wherein said treating comprises treating insomnia, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, myrcene, ocimene, linalool and combinations thereof, and wherein said non-volatile terpene is selected from the group consisting of caryophyllene, nerolidol, bisabolol and combinations thereof.
19. The composition for use of claim 16, wherein said treating comprises treating a condition selected from the group consisting of pain, joint pain, joint stiffness, arthralgia, arthritis, osteoarthritis, muscle pain, myalgia, spasticity, muscle tension, cramps, spasms, gastrointestinal pain, abdominal pain, pelvic pain, endometriosis, dysmenorrhea and combinations thereof wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, myrcene, limonene, linalool, terpineol and combinations thereof, and wherein said non-volatile terpene is selected from the group consisting of caryophyllene, humulene, nerolidol, bisabolol and combinations thereof.
20. The composition for use of claim 14, wherein said treating comprises treating a condition selected from the group consisting of pain, joint pain, joint stiffness, arthralgia, arthritis, osteoarthritis, muscle pain, myalgia, spasticity, muscle tension, cramps, spasms, gastrointestinal pain, abdominal pain, pelvic pain, endometriosis, dysmenorrhea and combinations thereof, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, myrcene, limonene, linalool, terpineol and combinations thereof, and wherein said non-volatile terpene is selected from the group consisting of caryophyllene, humulene, nerolidol, bisabolol and combinations thereof. 26
21. The composition for use of claim 16, wherein said treating comprises treating a condition selected from the group consisting of pain, neuropathic pain, migraine, headache and combinations thereof wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, myrcene, ocimene, linalool and combinations thereof, and wherein said non-volatile terpene is selected from the group consisting of caryophyllene, bisabolol and combinations thereof.
22. The composition for use of claim 14, wherein said treating comprises treating a condition selected from the group consisting of pain, neuropathic pain, migraine, headache and combinations thereof, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, myrcene, ocimene and combinations thereof, and wherein said non-volatile terpene is selected from the group consisting of caryophyllene, bisabolol and combinations thereof.
23. The composition for use of claim 14, wherein said treating comprises treating a condition selected from the group consisting of anxiety, stress, depression, irritability, general discomfort, nervousness, restless, mood problems and combinations thereof, wherein said at least one cannabinoid is selected from the group consisting of THC, CBD, THCV, CBDV, CBN, CBG, CBC, CBL and combinations thereof, wherein said at least two volatile terpenes are selected from the group consisting of pinene, limonene, terpinolene, eucalyptol, linalool and combinations thereof, and wherein said non-volatile terpene is selected from the group consisting of caryophyllene, humulene, nerolidol, guaiol, bisabolol and combinations thereof. 27
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032681P | 2020-05-31 | 2020-05-31 | |
| PCT/IB2021/054735 WO2021245522A1 (en) | 2020-05-31 | 2021-05-30 | Liquid cannabis compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL298623A true IL298623A (en) | 2023-01-01 |
Family
ID=78830860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL298623A IL298623A (en) | 2020-05-31 | 2021-05-30 | Liquid cannabis compositions and uses thereof |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2021285505A1 (en) |
| IL (1) | IL298623A (en) |
| WO (1) | WO2021245522A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022376838A1 (en) | 2021-10-26 | 2024-05-23 | Ecofibre USA Inc. | Methods of treating endometrial cancer using hemp extract |
| AU2022379618A1 (en) | 2021-10-26 | 2024-05-23 | Ecofibre USA Inc. | Methods of treating endometriosis and other non-cancer gynecological disorders with hemp extract |
| WO2023223172A1 (en) * | 2022-05-16 | 2023-11-23 | Buzzelet Development And Technologies Ltd. | Compositions comprising terpenes |
| WO2024091989A1 (en) | 2022-10-26 | 2024-05-02 | Ecofibre USA Inc. | Stabilized compositions comprising cannabidiol |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016138505A1 (en) * | 2015-02-27 | 2016-09-01 | Ebbu, LLC | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
| EP3664796A4 (en) * | 2017-08-13 | 2021-05-12 | Buzzelet Development And Technologies Ltd | Terpene-enriched cannabinoid composition and method of treatment |
-
2021
- 2021-05-30 AU AU2021285505A patent/AU2021285505A1/en active Pending
- 2021-05-30 IL IL298623A patent/IL298623A/en unknown
- 2021-05-30 WO PCT/IB2021/054735 patent/WO2021245522A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021285505A1 (en) | 2023-01-05 |
| WO2021245522A1 (en) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298623A (en) | Liquid cannabis compositions and uses thereof | |
| IL261629B2 (en) | Terpene-enriched cannabinoid composition | |
| AU2018101357A4 (en) | Composition and method for treating autism | |
| AU2018100837A4 (en) | Sleep Disorder Compositions and Treatments Thereof | |
| IL296008A (en) | Cannabis composition | |
| JP2021054836A (en) | Cannabis composition | |
| Dos Santos et al. | Linalool as a therapeutic and medicinal tool in depression treatment: A review | |
| Coronel et al. | Progesterone prevents nerve injury-induced allodynia and spinal NMDA receptor upregulation in rats | |
| Yang et al. | Edaravone alleviated propofol‐induced neural injury in developing rats by BDNF/TrkB pathway | |
| Chaachouay et al. | Cannabis sativa L.: a review on traditional uses, botany, phytochemistry, and pharmacological aspects | |
| KR20210071940A (en) | Cannabinoid compositions and methods for treating PTSD and/or anxiety | |
| KR20210153052A (en) | Agents for Treating Cluster Symptoms Associated with Autism Spectrum Disorder | |
| IL299008A (en) | Composition and method for treating chronic pain | |
| CA3103938A1 (en) | Compositions and methods for treatment of narcolepsy and related disorders | |
| Carreira et al. | Cannabinoids in the orthopedic setting: a literature review | |
| KR102634291B1 (en) | Ampoule for pain reduction surgery | |
| AU2021106137B4 (en) | Composition and method for treating chronic pain | |
| IL309022A (en) | Compositions and methods for treating epilepsy and/or autism | |
| Ohashi et al. | Omega-conotoxin MVIIA reduces neuropathic pain after spinal cord injury by inhibiting N-type voltage-dependent calcium channels on spinal dorsal horn | |
| PATIENT’S | PATIENT'S GUIDE TO CBD | |
| GAMELIN et al. | Email: francois-xavier. gamelin@ univ-lille. fr |